187例恶性肿瘤患者CA724增高结果分析-丁燕玲

　187CA724丁燕玲,赵应斌,容　亓,卢旭妹(广西壮族自治区柳州市人民医院检验科　545006)　　【】　　探讨血清CA724对消化系统和非消化系统恶性肿瘤的诊断价值。　用电化学发光免疫分析仪检测187例恶性肿瘤患者血清CA724,观察其中132例消化系统和55例非消化系统各部位恶性肿瘤所占的百分比率。　CA724增高前3位在消化系统恶性肿瘤组中肠癌占59.85%、胃癌占21.97%、肝癌占13.64%;非消化系统恶性肿瘤组中依次为肺癌占38.18%、子宫癌占29.09%、卵巢癌占23.64%。　CA724不仅可作为消化系统恶性肿瘤的良好指标,同时对非消化系统恶性肿瘤也有临床参考价值。【】　恶性肿瘤;　CA724;　电化学发光免疫DIO:10.3969/j.issn.1672-9455.2010.15.006:R730.43:A:1672-9455(2010)15-1548-01AnalysisonhighlevelofserumCA724inpatientswithmalignanttumorsin187cases　DINGYan-ling,ZHAOYing-bin,RONGQi,LUXu-mei.LiuzhouPeople′sHospital,Liuzhou,Guangxi545006,China【Abstract】　Objective　ToinvestigatethediagnosticvalueofserumCA724inmalignanttumorsofdigestivesystemandtheothersystems.Methods　SerumCA724levelsweremeasuredwithEIECSYSin187patientswithma-lignanttumors.Toobservethepercentageof132patientswithmalignanttumorsofdigestivesystemand55patientswithmalignanttumorsofothersystems.Results　Inthegroupofmalignanttumorsofdigestivesystem,thethreehighestlevelsofserumCA724wereintestinalcancer(59.85%),gastriccancer(21.97%)andlivercancer(23.64%).Inthegroupofmalignanttumorsofothersystems,thethreehighestlevelswerelungcancer(38.18%),uterinecancer(29.09%)andovariancancer(23.64%).Conclusion　SerumCA724isnotonlyagoodmarkerinmalignanttumorsofdigestivesystem,butalsoaclinicalreferencevalueinothersystems.【Keywords】　malignanttumor;　CA724;　electricchemicallightimmunoassay　　CA724,,,,[1]。187CA724,,,,。1　1.1　　187CA72420091～11X、B、CT、,110、77,22～87。1.2　　,Cobase411,,,,CA7246.9U/mL。1.3　　187CA724,CA724。2　　　2.1　187CA7247～300U/mL,22.99U/mL(7.06～300U/mL),17.96U/mL(7.18～300U/mL),(P0.05)。2.2　132CA724,1。1　187CA724(n=132)(n=55)n7929183212116132111%59.8521.9713.642.271.510.7638.1829.0923.643.641.821.821.82%42.2515.509.631.601.070.5311.238.566.951.070.530.530.533　　　CA724,[2-3],[4]。CA72459.85%、21.97%、13.64%,2.27%、1.51%、0.76%,CA724。,CA724(1551)·1548·检验医学与临床2010年8月第7卷第15期　LabMedClin,August2010,Vol.7,No.15,,;,“”,,、,、、,,,,,。,,,,,,、,。,。6mm,。,,、。,、[11]。,,,,。,,,,,、,,,,。,,,,,、,,。[1]EmeryJM,LitlleJH.Phacoemulsificationandaspirationofcataract[M].London:Mosby,1979:46-49.[2]MatsumotoK,IkedaK.Immunochemicalevidenceforin-creasedformationofadvancedglycationendproductsandinhibitionbyaminoguanidineindiabeticratlenses[J].BiochemBiophysResCommun,1997,241(2):352-354.[3]IversRQ,CummingRG,MitchellP,etal.Diabetesandriskoffracture:thebluemountainseyestudy[J].Diabe-tesCare,2001,24(7):1198-1203.[4],,.[J].,2000,35(4):211-212.[5],.[J].,2004,26(11):744-745.[6],,.[M].2.:,2001:356.[7]RossettiL,AutelitanoA.Cystoidmacularedemafollow-ingcataractsurgery[J].CurrOpinOphthalmol,2000,11:65-72.[8],,.[J].,2003,21(7):534-535.[9],,,.[J].,2001,9(4):296-298.[10],,,.[J].,1998,7(1):67-68.[11],,.[J].,2002,24(5):495-496.(:2010-03-03)(1548)[5]。CA72438.18%、29.09%、23.64%,3.64%、1.82%、1.82%、1.82%。,CA724,、。CA724,、、、、、、、、、、。CA724,。CA724,,、CA125、CA19-9,。[1],,.CA199,CA242CA724[J].,2007,38(5):430-432.[2]MatterR,AndradeCR,DifaveroGM,etal.PreoperativeserumlevelsofCA72-4,CEA,CA19-9andalpha-fetopro-teininpatientswithgasticcancer[J].RevHospClinFacMedUniSaoPaulo,2002,57(3):89-92.[3]GasparMJ,AmibasI,CocaMC,etal.PrognosticvalueofcarcinoembryonicantigenCA19-9andCA72-4ingastriccarcinoma[J].TumourBiol,2001,22(5):318-322.[4],,.CEA、CA19-9、CA72-4[J].,2005,18(2):127-128.[5].CEA、CA125、CA724[J].,2005,18(6):516-517.(:2010-02-28)·1551·检验医学与临床2010年8月第7卷第15期　LabMedClin,August2010,Vol.7,No.15